Market Place
Sourcing Support
Theratechnologies Releases EGRIFTA for HIV-Related Fat Reduction
05 Sep 2025 //
GLOBENEWSWIRE
Theratechnologies to be Acquired by CB Biotechnology
02 Jul 2025 //
GLOBENEWSWIRE
Theratechnologies Reports Q1 2025 Financial Results and Achievement
09 Apr 2025 //
GLOBENEWSWIRE
Theratechnologies gets FDA approval for Egifta SV® sBLA
08 Apr 2025 //
GLOBENEWSWIRE
Theratechnologies gets FDA approval for Egrifta WR to treat exces
25 Mar 2025 //
GLOBENEWSWIRE
Theratechnologies Presents Virologic Data From Ibalizumab Trial
12 Mar 2025 //
GLOBENEWSWIRE
Theratechnologies CROI Data Highlights BMI Limits In HIV CV Risk
12 Mar 2025 //
GLOBENEWSWIRE
Theratechnologies Resumes Distribution of EGRIFTA SV®
13 Feb 2025 //
GLOBENEWSWIRE
Theratechnologies Provides Update on EGRIFTA SV® Supply
09 Jan 2025 //
GLOBENEWSWIRE
Theratechnologies Files FDA Approval Supplement for Egrifta SV
18 Dec 2024 //
GLOBENEWSWIRE
Theratechnologies Receives March 2025 PDUFA Date
10 Dec 2024 //
GLOBENEWSWIRE
Theratech Announces Preliminary Sudocetaxel Data in Ovarian Cancer
09 Dec 2024 //
GLOBENEWSWIRE
Theratech Signs Agreement with Ionis for Olezarsen in Canada
04 Dec 2024 //
GLOBENEWSWIRE
Theratechnologies Submit Updated Tesamorelin F8 sBLA for FDA Review
26 Nov 2024 //
GLOBENEWSWIRE
Theratechnologies Reveals Trial Design For Ibalizumab People with HIV
17 Oct 2024 //
GLOBENEWSWIRE
Theratechnologies To Announce Third Quarter 2024 Results
26 Sep 2024 //
GLOBENEWSWIRE
Theratechnologies: TH1902 Long-Term Solid Tumor Data At ASCO 2024
02 May 2024 //
GLOBENEWSWIRE
Theratechnologies Preclinical Data Presentation at AACR 2024
08 Apr 2024 //
GLOBENEWSWIRE
Theratechnologies to Present Preclinical Data at AACR
28 Mar 2024 //
GLOBENEWSWIRE
Theratech Initiates Ph 1 Trial of Sudocetaxel Zendusortide in Ovarian Cancer
21 Mar 2024 //
GLOBENEWSWIRE
Theratechnologies Completes Enrollment in Ph 1 Trial of Sudocetaxel Zendusortide
15 Feb 2024 //
GLOBENEWSWIRE
Theratechnologies Receives Update from FDA on Tesamorelin F8 sBLA
23 Jan 2024 //
GLOBENEWSWIRE
Theratechnologies Submits sBLA for Trogarzo IM Method of Administration to FDA
02 Jan 2024 //
GLOBENEWSWIRE
Theratechnologies Ibalizumab Shows Cost-Effectiveness as an Addition to Routine
19 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Study
13 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Dosing of First Patient in Trial of Sudocetaxel Zendusortide
12 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Reports Financial Results for the Third Quarter
26 Sep 2023 //
GLOBENEWSWIRE
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
25 Sep 2023 //
GLOBENEWSWIRE
Theratechnologies All U.S. Onco Sites for Ph1 Trial of Sudocetaxel Zendusortide
30 Aug 2023 //
GLOBENEWSWIRE
Theratechnologies Investigator Call to Update on Sudocetaxel Zendusortide Trial
12 Jun 2023 //
GLOBENEWSWIRE
Canadian biotech amends trial protocol to get free from FDA hold
05 Jun 2023 //
FIERCE BIOTECH
Theratechnologies Receives Agreement to Amended Trial for Sudocetaxel Zendusortide
02 Jun 2023 //
GLOBENEWSWIRE
Theratechnologies to Present Data from Phase 1 Trial of Sudocetaxel Zendusortide
25 May 2023 //
GLOBENEWSWIRE
Theratechnologies™ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV
04 May 2023 //
GLOBENEWSWIRE
Theratechnologies Data at AACR 2023 Showcase Potential Sudocetaxel Zendusortide
18 Apr 2023 //
GLOBENEWSWIRE
Theratechnologies to Present Data at AACR Showing Synergy Between TH1902 & Anti-PD-L1
14 Mar 2023 //
GLOBENEWSWIRE
Theratechnologies Announces Path to Resume TH1902 Clinical Development
16 Feb 2023 //
GLOBENEWSWIRE
